Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Poolbeg Pharma Ltd. ( (GB:POLB) ).
Poolbeg Pharma has been granted a European patent for POLB 001, a p38 MAP kinase inhibitor, for treating severe influenza and cancer immunotherapy-induced Cytokine Release Syndrome. This strengthens Poolbeg’s global intellectual property portfolio, enhancing the value and appeal of POLB 001 to potential partners and addressing significant unmet medical needs in healthcare.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on transforming the cancer immunotherapy field. Its lead asset, POLB 001, aims to make cancer immunotherapies safer by preventing Cytokine Release Syndrome, potentially expanding treatment from specialist centers to community hospitals. The company is also developing a therapy for obesity and is focused on partnering its high-value programs targeting large markets and unmet medical needs.
Average Trading Volume: 1,373,792
Technical Sentiment Signal: Hold
Current Market Cap: £28.24M
For an in-depth examination of POLB stock, go to TipRanks’ Overview page.